The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV).
Data from a 2-part single-institution, open-label, dose-escalation phase I study showed a 75% overall response rate when idasanutlin was given as a monotherapy or in combination with pegylated interferon, said John Mascarenhas, MD, at the 2017 ASH Annual Meeting. Click the link below for the full story: